Gufic Biosciences invests USD 50,000 more in Selvax Pty Ltd

Gufic Biosciences Ltd has made a further investment of USD 50,000 in Selvax Pty Ltd, an Australian biotechnology company. This investment, completed on April 28, 2026, involved subscribing to 378,350 ordinary shares at AUD 20 cents per share. Selvax specializes in developing novel immunology-based treatments for large solid tumours, targeting both animal and human cancers. This strategic move aims to diversify Gufic Biosciences into the healthcare and biotechnology sector, providing access to proprietary technology and research capabilities in oncology. The company expects long-term benefits and value creation from this investment, aligning with its strategic diversification goals. Post-investment, Gufic Biosciences holds a total of 1,685,350 ordinary shares in Selvax. The transaction was for cash consideration and is not a related party transaction.